283 related articles for article (PubMed ID: 36952546)
1. Te Ara Waiora-Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial.
Gibson-Helm M; Slater T; MacDonald EJ; Stevenson K; Adcock A; Geller S; Parag V; Lambert C; Bennett M; Hibma M; Sykes P; Saville M; Hawkes D; Stanton JA; Clueard MA; Jelley G; Lawton B
PLoS One; 2023; 18(3):e0280643. PubMed ID: 36952546
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un- and under-screened Māori, Pacific and Asian women: study protocol for a randomised controlled community trial to examine the effect of self-sampling on participation in cervical-cancer screening.
Brewer N; Bartholomew K; Maxwell A; Grant J; McPherson G; Wihongi H; Bromhead C; Scott N; Crengle S; Cunningham C; Douwes J; Potter JD
BMC Cancer; 2019 Dec; 19(1):1198. PubMed ID: 31815615
[TBL] [Abstract][Full Text] [Related]
3. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus (HPV) Self-Sampling among Never-and Under-Screened Indigenous Māori, Pacific and Asian Women in Aotearoa New Zealand: A Feasibility Study.
Bromhead C; Wihongi H; Sherman SM; Crengle S; Grant J; Martin G; Maxwell A; McPherson G; Puloka '; Reid S; Scott N; Bartholomew K
Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639352
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and acceptability of telehealth and contactless delivery of human papillomavirus (HPV) self-testing for cervical screening with Māori and Pacific women in a COVID-19 outbreak in Aotearoa New Zealand.
Bartholomew K; Grant J; Maxwell A; Bromhead C; Gillett F; Saraf R; Moodabe K; Sherman SM; McPherson G; Flower D; Kathuria J; Crengle S; Massey R; Scott N; Coote P
N Z Med J; 2022 Nov; 135(1565):83-94. PubMed ID: 36356272
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
9. A Model for Empowering Rural Solutions for Cervical Cancer Prevention (He Tapu Te Whare Tangata): Protocol for a Cluster Randomized Crossover Trial.
Lawton B; MacDonald EJ; Storey F; Stanton JA; Adcock A; Gibson M; Parag V; Sparkes NK; Kaimoana B; King F; Terry M; Watson H; Bennett M; Lambert CS; Geller S; Paasi I; Hibma M; Sykes P; Hawkes D; Saville M
JMIR Res Protoc; 2023 Sep; 12():e51643. PubMed ID: 37707939
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
11. Community-randomised controlled trial embedded in the Anishinaabek Cervical Cancer Screening Study: human papillomavirus self-sampling versus Papanicolaou cytology.
Zehbe I; Jackson R; Wood B; Weaver B; Escott N; Severini A; Krajden M; Bishop L; Morrisseau K; Ogilvie G; Burchell AN; Little J
BMJ Open; 2016 Oct; 6(10):e011754. PubMed ID: 27855089
[TBL] [Abstract][Full Text] [Related]
12. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.
Tranberg M; Bech BH; Blaakær J; Jensen JS; Svanholm H; Andersen B
BMC Cancer; 2016 Nov; 16(1):835. PubMed ID: 27809810
[TBL] [Abstract][Full Text] [Related]
14. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
15. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
16. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
17. Preliminary assessment of using mobile point-of-care human papillomavirus (HPV) testing with the option of immediate colposcopy in a rural area in a high-income country: a case study.
Paterson H; Macfarlane E; Slater T; Stanton JL; MacDonald EJ; Gibson M; Lawton B
N Z Med J; 2024 Jun; 137(1596):43-51. PubMed ID: 38843549
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and sociodemographic predictors of high-risk vaginal human papillomavirus infection: findings from a public cervical cancer screening registry.
Jailani AS; Balqis-Ali NZ; Tang KF; Fun WH; Samad SA; Jahaya R; Subakir NN; Ismail R; Said ZM; Sararaks S
BMC Public Health; 2023 Nov; 23(1):2243. PubMed ID: 37964260
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
